Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy-Reference-Cited by-同舟云学术

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Published:2023-07 Issue:7 Volume:29 Page:430-437
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Gazeau Nicolas^ORCID,Liang Emily C.^ORCID,Wu Qian “Vicky”,Voutsinas Jenna M.,Barba Pere,Iacoboni Gloria^ORCID,Kwon Mi^ORCID,Ortega Juan Luis Reguera,López-Corral Lucía,Hernani Rafael^ORCID,Ortiz-Maldonado Valentín^ORCID,Martínez-Cibrian Nuria^ORCID,Martinez Antonio Perez^ORCID,Maziarz Richard T.^ORCID,Williamson Staci,Nemecek Eneida R.,Shadman Mazyar,Cowan Andrew J.^ORCID,Green Damian J.^ORCID,Kimble Erik^ORCID,Hirayama Alexandre V.^ORCID,Maloney David G.,Turtle Cameron J.,Gauthier Jordan^ORCID

Funder

National Cancer Institute

National Institutes of Health

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference30 articles.

1. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N Engl J Med,2018

2. US Food and Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. January 31, 2022. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic. Accessed May 31, 2022.

3. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

4. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial;Locke;Lancet Oncol,2019

5. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial;Jacobson;Lancet Oncol,2022

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cytokine networks in neuroinflammatory diseases;Nature Reviews Drug Discovery;2024-09-11

2. Need for standardization of cytokine profiling in CAR T cell therapy;Molecular Therapy;2024-09

3. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities;Intensive Care Medicine;2024-08-22

4. Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers;Cytotherapy;2024-08

5. Late-onset relapsing neurotoxicity after Brexucabtagene autoleucel associated with high chimeric antigen receptor T cells in cerebrospinal fluid;Cytotherapy;2024-08